Invokana (canaglifozin) For Type 2 Diabetes Approved By FDA

Editor’s Choice
Main Category: Diabetes
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 31 Mar 2013 – 0:00 PDT

email to a friend   printer friendly   opinions  

<!– rate article

Patient / Public:

Healthcare Prof:

The FDA has approved Johnson Johnson’s Invokana (canaglifozin) tablets, to be used with exercise and diet, for adults with type 2 diabetes to improve glycemic control.

Type 2 diabetes affects approximately 24 million Americans. Patients eventually tend to have complications from high blood sugar levels, including kidney damage, nerve damage, blindness and heart disease.

Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research, said:

“Invokana is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. We continue to advance innovation with the approval of new drug classes that provide additional treatment options for chronic conditions that impact public health.”

Invokana stops the kidney from reabsorbing glucose, increasing glucose excretion, and reducing blood glucose levels in patients with diabetes who have excessively high blood glucose levels.

Richard Aguilar, M.D., Medical Director, Diabetes Nation LLC and the Diabetes Care Foundation, said “Patients with type 2 diabetes struggle managing their blood sugar, and nearly half of adults with type 2 diabetes do not achieve recommended levels of glucose control, increasing their risks for potentially life-threatening complications. Invokana is thought to work differently than other currently-available medicines because it reduces blood glucose by acting on the kidneys as a ‘glucuretic,’ increasing the loss of glucose in the urine. What has historically been viewed as a sign of diabetes – glucose in the urine – may also reflect the efficacy of a new and unique approach to treatment.”

Invokana’s safety and efficacy were assessed in nine clinical trials involving 10,285 type 2 diabetes patients. Patients on Invokana experienced improved A1c levels and fasting blood sugar (plasma glucose) levels. In Phase III studies, Invokana was also associated with reductions in body weight and systolic blood pressure.

Invokana has been studied as therapy to be taken on its own, and also in combination with, pioglitazone, sulfonylurea, metformin and insulin.

Invokana should not be used for patients with:

  • Type 1 diabetes
  • Diabetic ketoacidosis – ketones in their urine or blood
  • Severe renal (kidney) impairment
  • End stage kidney disease
  • On dialysis

According to the FDA, Janssen Pharmaceuticals, Inc. (part of Johnson Johnson) will have to carry out post-marketing studies:

  • A cardiovascular outcomes trial to check for liver abnormalities, photosensitivity reactions, adverse pregnancy outcomes, malignancies, severe hypersensitivity reactions, and serious cases of pancreatitis.
  • A bone safety study
  • Two studies on children under the Pediatric Research Equity Act (PREA). These should include a safety and efficacy study and a pharmacokinetic and pharmacodynamic study.

The following side effects were reported during the Invokana trials: urinary tract infection and vulvovaginal candidiasis.

Invokana’s diuretic effect can cause a sudden fall in blood pressure when the patient stands up (postural or orthostatic hypotension) – symptoms include fainting or dizziness. This is more common during the first twelve weeks of therapy.

Invokana is made by Janssen Pharmaceuticals, Inc., Titusville, N.J.

One month ago the FDA approved Nesina (alogliptin) tablets, Oseni (alogliptin and pioglitazone) tablets, and Kazano (alogliptin and metformin hydrochloride) tablets, to improve blood sugar control.

Written by Christian Nordqvist

Copyright: Medical News Today

Not to be reproduced without permission of Medical News Today

  • Additional
  • References
  • Citations

Please use one of the following formats to cite this article in your essay, paper or report:



Please note: If no author information is provided, the source is cited instead.

Add Your Opinion On This Article

‘Invokana (canaglifozin) For Type 2 Diabetes Approved By FDA’

Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

Privacy Policy |
Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2013 All rights reserved.
MNT (logo) is the registered trade mark of MediLexicon International Ltd.

back to top | home |
privacy policy

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2013 All rights reserved.
MNT (logo) is the registered trade mark of MediLexicon Int. Limited.